Yes. And in many instances, it is the preferred treatment.
Our library contains extensive scientific references from peer reviewed papers which will provide you with factual evidence regarding the use of whole umbilical cord blood. Our policy statement on whole cord blood is a cumulative document detailing all the peer reviewed literature which supports the use of whole cord blood.
Whole cord blood is stored to ensure that in the future the maximum possible use can be made of the sample. As you are considering this option, you are aware that the statistical analysis of developing childhood leukaemia is 1 in 20,000. You are also aware of the potential in regenerative medicine being discussed in the media. Whole cord blood contains all the different types of cells, haematopoietic, VSELS, Mesenchymal stem cells, other stem cell types, not to mention hormones and growth factors which comprise the whole cord blood sample.
It is these other types of stem cells which are the focus of medical research and which increase the use of cord blood way beyond treatment of blood disorders.
Commercial extraction methods are focussed on the CD34+ stem cell population, a subsection of the whole stem cell population. This sub-population is the one which has been identified as being the major source of cells which reconstitute the bone marrow in individuals with illnesses such as leukaemia.
Public health institutions have a policy of increasing the stocks of stem cell to provide treatments for leukaemia patients. This is becoming more popular as the number of bone marrow donors is insufficient for the number of patients and the use of multiple partially-mismatched cord blood units to treat adults is becoming common practice. As such the CD34+ sub-population is of key interest to public health banks.
The public health banks have to maximise the storage capacity available, and an effective method of doing this is to reduce the volume of the samples increasing the number in a tank. Extracting the CD34+ population has become possible by developments in technology. This minimises the amount of sample stored, whilst (for blood disorders) providing a clinically viable sample.
Other private cord blood banks have utilised this technology, effectively ensuring the samples they store are identical in nature to those store in a public bank, but without the foresight and technical expertise to future proof the sample. The skill level required in the laboratory is also lower, as this is automated technology.
Privately banked cord blood samples are not stored with the aim of treating a child with leukaemia, especially in the UK; they are stored because of the possible future uses and other diseases which can be treated using stem cells. The future of stem cell therapy is the driving reason.
Cells4Life has been able to demonstrate via independent peer reviewed papers (see library) that the minimally invasive cryopreservation technique of storing whole cord blood does provide a significantly larger and more diverse population of stem cell types, which are clinically superior even in blood disorder treatments.
Why throw the baby out with the bathwater? Extracting CD34+ stem cells is limiting the use of the sample, and at a time when technology and medicine are advancing rapidly, why would you limit the possibilities?








